Inhibitory effects of persistent apoptotic cells on monoclonal antibody production in vitro: simple removal of non-viable cells improves antibody productivity by hybridoma cells in culture.
Cells undergoing apoptosis in vivo are rapidly detected and cleared by phagocytes. Swift recognition and removal of apoptotic cells is important for normal tissue homeostasis and failure in the underlying clearance mechanisms has pathological consequences associated with inflammatory and auto-immune diseases. Cell cultures in vitro usually lack the capacity for removal of non-viable cells because of the absence of phagocytes and, as such, fail to emulate the healthy in vivo micro-environment from which dead cells are absent. While a key objective in cell culture is to maintain viability at maximal levels, cell death is unavoidable and non-viable cells frequently contaminate cultures in significant numbers. Here we show that the presence of apoptotic cells in monoclonal antibody-producing hybridoma cultures has markedly detrimental effects on antibody productivity. Removal of apoptotic hybridoma cells by macrophages at the time of seeding resulted in 100% improved antibody productivity that was, surprisingly to us, most pronounced late on in the cultures. Furthermore, we were able to recapitulate this effect using novel super-paramagnetic Dead-Cert Nanoparticles to remove non-viable cells simply and effectively at culture seeding. These results (1) provide direct evidence that apoptotic cells have a profound influence on their non-phagocytic neighbors in culture and (2) demonstrate the effectiveness of a simple dead-cell removal strategy for improving antibody manufacture in vitro.
Gregory
Christopher D
CD
Immunosolv Limited, Edinburgh, EH16 4SB, UK. chris.gregory@immunosolv.com
Pound
John D
JD
Devitt
Andrew
A
Wilson-Jones
Megan
M
Ray
Parthasarathi
P
Murray
Ruth J
RJ
D000911:Antibodies, Monoclonal / Q000096:biosynthesis*; D017209:Apoptosis; D018929:Cell Culture Techniques / Q000379:methods*; D002470:Cell Survival; D006801:Humans; D006825:Hybridomas / Q000166:cytology*; D015202:Protein Engineering / Q000379:methods / Q000639:trends*
D000911:Antibodies, Monoclonal